Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Vir Biotechnology, Inc.NASDAQ: VIR

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital turns negative

Q1 FY2026 other working capital was -$18.46M, compared with $27.47M a year earlier. Trailing-twelve-month other working capital was -$73.38M. Over 3 fiscal years it compounded at -36.2% a year.

Context

  • Other working capital amounted to 40.0% of revenue in FY2025, down 63.1 pp from a year earlier.
  • Other working capital grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other working capital holds near -$18.46M or moves back toward the trailing-twelve-month quarterly average of -$18.34M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.46M+218.3% QoQ
Last fiscal yearDec 2025
-$27.44M-64.1% YoY
LTMMar 2026
-$73.38M-319.4% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-167.2%——
1 year-64.1%——
3-year CAGR-36.2%——
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
(27.44M) USD
Year-over-year change
+64.1%

Other Working Capital vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -319.4% is the lowest of 9, against a peer median of +158.3%.
  • Other working capital amounts to 112.0% of revenue for VIR, versus a peer median of 10.1%.
VIR Competitors
Other Working Capital for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$519M USD+676.7%—20.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$73.38M USD-319.4%-36.2%112.0%
NVAXNovavax, Inc.LTM Mar 2026$69.9M USD-86.8%-15.9%11.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$42.33M USD+4.2%+204.8%4.5%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$36.58M USD+102.5%+204.1%51.5%
VALNValneva SELTM Mar 2026€25.29M EUR+214.1%-60.1%16.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$16.41M USD+7981.6%—8.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$11.83M USD+225.4%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.56M USD-89.6%—2.2%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
Peer median (excluding VIR) —+158.3%+94.1%10.1%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Depreciation & Amortization5.81M6.78M19.45M14.56M21.15M
Deferred Income Tax15.19M(15.19M)(1.06M)(2.95M)0
Stock-Based Compensation83.78M102.08M078.46M49.07M
Change in Working Capital(628.39M)665.37M(304.59M)(84.01M)(22.45M)
Accounts Receivables(773.08M)770.04M(565K)(6.51M)0
Inventory52.82M0000
Accounts Payables(171K)797K732K(988K)5M
Other Working Capital92.04M(105.47M)(304.76M)(76.51M)(27.44M)
Other Non-Cash Items(52.56M)388.37M122.48M69.55M(1.57M)
Operating Cash Flow(47.59M)1.66B(778.79M)(446.35M)(391.78M)
Capital Expenditures(21.82M)(68.01M)(21.57M)(7.3M)(4.83M)
Acquisitions (Net)140.81M0100K3.37M253K
Purchases of Investments(420.24M)(1.48B)(2.02B)(1.24B)(886.33M)
Sales of Investments301.24M351.51M2.2B1.74B1.2B
Other Investing Activities(140.81M)0000
Investing Cash Flow(140.81M)(1.19B)164.73M499.37M310.37M
Debt Repayment(259K)(260K)(287K)(165K)(361K)
Common Stock Issued85.21M28.46M7.77M4.55M4.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.38M6.56M(100K)00
Financing Cash Flow100.33M34.76M7.38M4.39M3.79M
Effect of Forex Changes00208K00
Net Change in Cash(88.07M)504.55M(606.47M)57.4M(77.63M)
Free Cash Flow(69.41M)1.6B(800.36M)(453.65M)(396.61M)

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.